TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) insider Tamer I. Khayal sold 15,512 shares of TransMedics Group stock in a transaction dated Tuesday, April 9th. The stock was sold at an average price of $90.45, for a total value of $1,403,060.40. Following the completion of the transaction, the insider now owns 25,185 shares of the company's stock, valued at $2,277,983.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
TransMedics Group Stock Performance
TMDX opened at $95.65 on Thursday. The business's 50 day moving average is $82.59 and its 200-day moving average is $71.60. The stock has a market cap of $3.13 billion, a PE ratio of -124.22 and a beta of 1.99. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69. TransMedics Group, Inc. has a twelve month low of $36.42 and a twelve month high of $99.63.
TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its earnings results on Monday, February 26th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.22. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The firm had revenue of $81.20 million for the quarter, compared to analysts' expectations of $68.49 million. During the same quarter in the previous year, the company earned ($0.21) earnings per share. The firm's quarterly revenue was up 158.6% compared to the same quarter last year. On average, analysts predict that TransMedics Group, Inc. will post -0.14 earnings per share for the current year.
Institutional Investors Weigh In On TransMedics Group
Protect Your Bank Account Before It’s Too Late
From Weiss Ratings | Ad
For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account.
It gives them the power to monitor every single transaction …
Stop right now and do these 3 things to protect yourself
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Harbour Capital Advisors LLC raised its holdings in TransMedics Group by 1.7% during the fourth quarter. Harbour Capital Advisors LLC now owns 8,371 shares of the company's stock worth $627,000 after purchasing an additional 140 shares in the last quarter. First Horizon Advisors Inc. raised its holdings in TransMedics Group by 45.1% during the first quarter. First Horizon Advisors Inc. now owns 544 shares of the company's stock worth $41,000 after purchasing an additional 169 shares in the last quarter. Belpointe Asset Management LLC raised its holdings in TransMedics Group by 51.6% during the first quarter. Belpointe Asset Management LLC now owns 558 shares of the company's stock worth $42,000 after purchasing an additional 190 shares in the last quarter. RiverPark Advisors LLC raised its holdings in TransMedics Group by 19.5% during the fourth quarter. RiverPark Advisors LLC now owns 1,319 shares of the company's stock worth $104,000 after purchasing an additional 215 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in TransMedics Group by 2.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,512 shares of the company's stock worth $896,000 after purchasing an additional 288 shares in the last quarter. Institutional investors own 99.67% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on TMDX shares. Morgan Stanley lifted their price target on TransMedics Group from $75.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. lifted their target price on TransMedics Group from $87.00 to $105.00 and gave the company an "overweight" rating in a research note on Tuesday, February 27th. Piper Sandler began coverage on TransMedics Group in a research note on Thursday, March 28th. They issued an "overweight" rating and a $95.00 target price for the company. Finally, Oppenheimer lifted their target price on TransMedics Group from $92.00 to $105.00 and gave the company an "outperform" rating in a research note on Tuesday, February 27th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, TransMedics Group presently has a consensus rating of "Moderate Buy" and a consensus price target of $102.00.
View Our Latest Stock Analysis on TMDX
TransMedics Group Company Profile
(
Get Free Report)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
